Botanix Pharmaceuticals Limited
BXPHF
$0.04
$0.0010.88%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 945.18% | 556.73% | 170.50% | 204.33% | 374.95% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 945.18% | 556.73% | 170.50% | 204.33% | 374.95% |
| Cost of Revenue | 116.12% | 59.75% | 1.00% | 43.49% | 139.32% |
| Gross Profit | 828.88% | 544.81% | 220.98% | 102.27% | -52.89% |
| SG&A Expenses | 148.90% | 245.83% | 557.26% | 481.34% | 368.27% |
| Depreciation & Amortization | 92.52% | 252.51% | 2,971.91% | 1,833.33% | 1,035.32% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 144.34% | 222.21% | 441.60% | 385.99% | 303.94% |
| Operating Income | -103.46% | -196.99% | -481.75% | -404.91% | -300.87% |
| Income Before Tax | -119.49% | -217.72% | -510.81% | -416.66% | -290.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -119.49% | -217.72% | -510.81% | -416.66% | -290.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -119.49% | -217.72% | -510.81% | -416.66% | -290.08% |
| EBIT | -103.46% | -196.99% | -481.75% | -404.91% | -300.87% |
| EBITDA | -103.79% | -195.67% | -468.77% | -392.63% | -289.88% |
| EPS Basic | -101.35% | -183.81% | -400.00% | -312.96% | -208.33% |
| Normalized Basic EPS | -101.08% | -183.33% | -394.74% | -311.76% | -200.00% |
| EPS Diluted | -101.35% | -183.81% | -400.00% | -312.96% | -208.33% |
| Normalized Diluted EPS | -101.08% | -183.33% | -394.74% | -311.76% | -200.00% |
| Average Basic Shares Outstanding | 13.48% | 17.90% | 22.87% | 23.45% | 24.08% |
| Average Diluted Shares Outstanding | 13.48% | 17.90% | 22.87% | 23.45% | 24.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |